P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA

• Julia Piasecki,
• Keyur Desai,
• Carolyn Courtney,
• Ethan Thompson,
• James Pratt,
• Noopur Raje,
• Krina Patel,
• Marc S. Raab,
• Mark Cook,
• Katy Simonsen,
• Mihaela Popa Mckiver,
• Shari Kaiser,
• Nathan Martin

Affiliations

Julia Piasecki

1 Bristol Myers Squibb, Seatle, United States

Keyur Desai

2 Bristol Myers Squibb, Princeton, United States

Carolyn Courtney

2 Bristol Myers Squibb, Princeton, United States

Ethan Thompson

1 Bristol Myers Squibb, Seatle, United States

James Pratt

2 Bristol Myers Squibb, Princeton, United States

Noopur Raje

3 Massachusetts General Hospital, Boston, United States

Krina Patel

4 MD Anderson Cancer Center, Houston, United States

Marc S. Raab

5 Heidelberg University Hospital, Heidelberg, Germany

Mark Cook

6 Bristol Myers Squibb, Boudry, Switzerland

Katy Simonsen

2 Bristol Myers Squibb, Princeton, United States

Mihaela Popa Mckiver

2 Bristol Myers Squibb, Princeton, United States

Shari Kaiser

1 Bristol Myers Squibb, Seatle, United States

Nathan Martin

1 Bristol Myers Squibb, Seatle, United States